Alphatec (NASDAQ:ATEC) EVP David Sponsel Sells 137,445 Shares

Key Points

• Alphatec's EVP, David Sponsel, sold $2,074,045.05 worth of stock, decreasing his ownership by 20.46% to 534,416 shares.
• The company's stock has recently increased by 2.1% to a trading price of $15.54, with a market cap of $2.30 billion.
• Alphatec reported a quarterly revenue increase of 27.5%, totaling $185.54 million, and is projected to have an EPS of -1.08 for the current fiscal year.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) EVP David Sponsel sold 137,445 shares of the stock in a transaction on Thursday, September 18th. The stock was sold at an average price of $15.09, for a total transaction of $2,074,045.05. Following the transaction, the executive vice president directly owned 534,416 shares in the company, valued at $8,064,337.44. The trade was a 20.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

David Sponsel also recently made the following trade(s):

• On Friday, September 19th, David Sponsel sold 2,555 shares of Alphatec stock. The stock was sold at an average price of $15.34, for a total transaction of $39,193.70.

Alphatec Stock Up 0.4%

Alphatec stock traded up $0.06 during mid-day trading on Monday, hitting $15.60. 1,373,090 shares of the company's stock were exchanged, compared to its average volume of 1,936,744. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22. The stock has a market cap of $2.31 billion, a P/E ratio of -13.81 and a beta of 1.02. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $16.70. The stock has a 50 day moving average of $14.32 and a two-hundred day moving average of $12.24.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.08. The firm had revenue of $185.54 million for the quarter, compared to the consensus estimate of $178.85 million. Alphatec had a negative net margin of 24.33% and a negative return on equity of 1,657.19%. The business's quarterly revenue was up 27.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.29) earnings per share. Alphatec has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Alphatec

Several hedge funds have recently made changes to their positions in the stock. Osaic Holdings Inc. lifted its stake in shares of Alphatec by 22.3% in the second quarter. Osaic Holdings Inc. now owns 36,242 shares of the medical technology company's stock valued at $402,000 after buying an additional 6,616 shares during the period. Squarepoint Ops LLC lifted its stake in shares of Alphatec by 24.0% in the second quarter. Squarepoint Ops LLC now owns 239,870 shares of the medical technology company's stock valued at $2,663,000 after buying an additional 46,349 shares during the period. State of Wyoming bought a new stake in shares of Alphatec in the second quarter valued at about $124,000. Tower Research Capital LLC TRC lifted its stake in shares of Alphatec by 536.4% in the second quarter. Tower Research Capital LLC TRC now owns 14,815 shares of the medical technology company's stock valued at $164,000 after buying an additional 12,487 shares during the period. Finally, Captrust Financial Advisors lifted its stake in shares of Alphatec by 337.5% in the second quarter. Captrust Financial Advisors now owns 49,195 shares of the medical technology company's stock valued at $546,000 after buying an additional 37,950 shares during the period. Institutional investors own 66.35% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research report on Friday, August 1st. Barclays reaffirmed an "overweight" rating and issued a $22.00 price target (up from $21.00) on shares of Alphatec in a research report on Monday, August 4th. Wall Street Zen raised Alphatec from a "hold" rating to a "buy" rating in a research report on Sunday, September 7th. Finally, Lake Street Capital raised Alphatec to a "buy" rating and set a $18.00 price target on the stock in a research report on Monday, June 16th. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $18.50.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.